Tetanus toxoid peptide-MHC class II-T cell receptor complex (TT-pMHCII-TCR)

The Tetanus toxoid-derived peptide-MHC class II-T cell receptor (TT-pMHCII-TCR) interface is a multi-protein complex essential for the activation of CD4+ T helper cells. Tetanus toxoid (TT), a chemically inactivated form of the tetanus toxin produced by Clostridium tetani, contains highly immunogenic universal epitopes such as p2 (830–844) and p30 (947–967) (Panina-Bordignon et al., 1989, PMID: 2571463). These peptides are processed by antigen-presenting cells and loaded onto Major Histocompatibility Complex (MHC) class II molecules, most commonly HLA-DR, for presentation to the T cell receptor (TCR) (Demotz et al., 1989, PMID: 2528604). The formation of this tripartite complex triggers a signaling cascade that leads to T cell proliferation and the production of inflammatory cytokines.\n\nIn therapeutic contexts, this interface is frequently utilized as a helper system in vaccines; by conjugating or co-administering TT peptides with other antigens, clinicians can recruit pre-existing memory T cells to enhance the immune response against pathogens or tumors (Fenstermaker et al., 2016, PMID: 27846254). This strategy is particularly prominent in the development of cancer vaccines, such as SurVaxM, where TT peptides provide the necessary T cell help to overcome the immunosuppressive tumor microenvironment (Ciesielski et al., 2023, PMID: 36516124). Consequently, the TT-pMHCII-TCR interface serves as a potent tool for enhancing vaccine efficacy and overcoming immune tolerance in oncology.

Other names

Tetanus toxoid epitope-MHC-TCR interfaceTT-pMHCII complexTetanus toxoid-derived peptide-HLA-DR-TCR complexTT-pMHC-TCR interface

Activation of CD4+ T helper cells through the recognition of tetanus-derived epitopes presented on MHC class II molecules, leading to cytokine release and enhancement of the overall immune response.